Search Results - "Irby, Donald J."

Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics by Irby, Donald J., Ibrahim, Mustafa E., Dauki, Anees M., Badawi, Mohamed A., Illamola, Sílvia M., Chen, Mingqing, Wang, Yuhuan, Liu, Xiaoxi, Phelps, Mitch A., Mould, Diane R.

“…Missing or erroneous information is a common problem in the analysis of pharmacokinetic (PK) data. This may present as missing or inaccurate dose level or dose…”
Get full text

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans by Castillo, Alyssa Marie M., Vu, Trang T., Liva, Sophia G., Chen, Min, Xie, Zhiliang, Thomas, Justin, Remaily, Bryan, Guo, Yizhen, Subrayan, Uma L., Costa, Travis, Helms, Timothy H., Irby, Donald J., Kim, Kyeongmin, Owen, Dwight H., Kulp, Samuel K., Mace, Thomas A., Phelps, Mitch A., Coss, Christopher C.

“…Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about…”
Get full text

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant by Cho, Yu Kyoung, Irby, Donald J., Li, Junan, Sborov, Douglas W., Mould, Diane R., Badawi, Mohamed, Dauki, Anees, Lamprecht, Misty, Rosko, Ashley E., Fernandez, Soledad, Hade, Erinn M., Hofmeister, Craig C., Poi, Ming, Phelps, Mitch A.

“…High‐dose melphalan (HDM) is part of the conditioning regimen in patients with multiple myeloma (MM) receiving autologous stem cell transplantation (ASCT)…”
Get full text